4D Molecular Therapeutics Inc (FDMT) — Financial Flexibility Index
4D Molecular Therapeutics Inc (FDMT) has a Financial Flexibility Index of 0.48x as of December 2025. Free cash flow of $29.18 Million (operating CF $28.55 Million minus capex $631.00K) represents 0% of total liabilities ($61.05 Million). Check FDMT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
4D Molecular Therapeutics Inc Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for 4D Molecular Therapeutics Inc across 9 annual periods. For the full cash flow conversion analysis, see FDMT cash flow metrics.
Annual Financial Flexibility Index for 4D Molecular Therapeutics Inc (2017–2025)
Year-by-year free cash flow to debt coverage for 4D Molecular Therapeutics Inc. Explore 4D Molecular Therapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.78x | $-108.55 Million | $-109.08 Million | $61.05 Million | ▲ +32.3% |
| 2024 | -2.63x | $-130.80 Million | $-134.59 Million | $49.78 Million | ▼ -15.4% |
| 2023 | -2.28x | $-73.02 Million | $-75.79 Million | $32.06 Million | ▲ +7.5% |
| 2022 | -2.46x | $-75.15 Million | $-86.69 Million | $30.51 Million | ▼ -41.1% |
| 2021 | -1.75x | $-60.02 Million | $-69.13 Million | $34.38 Million | ▼ -11.7% |
| 2020 | -1.56x | $-49.91 Million | $-50.91 Million | $31.94 Million | ▼ -511.8% |
| 2019 | -0.26x | $-33.51 Million | $-36.71 Million | $131.20 Million | ▼ -100.8% |
| 2018 | -0.13x | $-15.84 Million | $-16.25 Million | $124.56 Million | ▼ -167.7% |
| 2017 | 0.19x | $8.81 Million | $8.24 Million | $46.91 Million | — |